European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC
EBAC was delisted on the 2nd of March, 2023.
46 hedge funds and large institutions have $71.7M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
2% more funds holding
Funds holding: 45 → 46 (+1)
1.49% more ownership
Funds ownership: 54.19% → 55.68% (+1.5%)
3% more capital invested
Capital invested by funds: $69.6M → $71.7M (+$2.09M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.65M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.53M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$1.78M |
| 4 |
SC
Sculptor Capital
New York
|
+$1.58M |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$1.92M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.32M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$937K |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$383K |
| 5 |
AMH
Apollo Management Holdings
New York
|
-$63.2K |
EBAC Hedge Fund Activity: Q1 2022 in Review
46 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q1 2022, worth a combined $71.7M — up 3% from $69.6M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EBAC positions and 4 closed out — a net gain of 2 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.65M. The largest seller was Arena Capital Advisors, cutting an estimated $1.92M.
- 46 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q1 2022, up from 45 in Q4 2021.
- Funds reported $71.7M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q1 2022, up 3% quarter-over-quarter.
- 6 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q1 2022 and 4 closed out, a net change of +2 holders.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q1 2022 was Millennium Management, an estimated $4.65M added.
- The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q1 2022 was Arena Capital Advisors, an estimated $1.92M sold.
Based on aggregated 13F filings for Q1 2022.